AU Patent

AU2020346456A1 — TAK-925 for use in treating narcolepsy

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2022-04-14 · 4y expired

What this patent protects

A method for treating narcolepsy type 1 in a subject in need thereof is disclosed, comprising administering to the subject an effective amount of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate (Compound (I)), or a salt thereof, wherei…

USPTO Abstract

A method for treating narcolepsy type 1 in a subject in need thereof is disclosed, comprising administering to the subject an effective amount of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate (Compound (I)), or a salt thereof, wherein plasma concentration for Compound (I) is about 5.04 ng/mL or more for about 1 hour or more. Compositions for treating narcolepsy type 1 comprising Compound (I) are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020346456A1
Jurisdiction
AU
Classification
—
Expires
2022-04-14
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.